BioHarvest Sciences Inc

BioHarvest Sciences Inc(BHST)の株式分析

$1.580

+0.095 (+6.04%)終値時点

Loading chart…
高値
1.660
始値
1.510
出来高加重平均価格
1.57
出来高
55.74K
時価総額
—
安値
1.460
売買代金
87.32K
EV/EBITDA(TTM)
-2.85

BioHarvest Sciences Inc. is a Canada-based botanical synthesis company. The Company leverages its technology platform to grow plant-based compounds, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop science-based therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking plant-based compounds, and as a creator of nutraceutical health and wellness products, which include dietary supplements. It delivers phytochemicals such as age-defying antioxidants and polyphenols used for wellness. Its product pipeline is focused on polyphenols, which include grape cells, olive cells, and pomegranate cells. Its process involves selecting the specific plant cells that can create the targeted ingredients. It offers VINIA, which is a nutraceutical containing the entire matrix of polyphenols contained in red grapes, including Piceid resveratrol.

bioharvest.com/about

AI分析 of BioHarvest Sciences Inc (BHST)

中立

Bioharvest Sciences Inc (BHST) is currently not a strong buy due to its low RSI of 32.086, indicating oversold conditions, and a significant year-to-date change of -69.87%. However, the company has shown revenue growth of 8% year-over-year in Q1 2026, with a projected annual revenue guidance of $42 million to $48 million, suggesting potential for recovery. The main risk is the forward P/E of 153.846, indicating high valuation expectations despite ongoing losses.

バリュエーション指標

BioHarvest Sciences Inc(BHST)の現在の予想PERは153.85で、5年平均は66.35です。

予想PER

適正
5年平均 P/E
66.35
現在のP/E
153.85
割高
162.88
割安
-30.18

予想EV/EBITDA

適正
5年平均 EV/EBITDA
167.45
現在のEV/EBITDA
-2.85
割高
801.58
割安
-466.68

予想PSR

割安
5年平均 P/S
2.31
現在のP/S
0.68
割高
3.47
割安
1.14

BHST のよくある質問 — Alphio AI が回答

BioHarvest Sciences Inc. is a Canada-based botanical synthesis company. The Company leverages its technology platform to grow plant-based compounds, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop science-based therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking plant-based compounds, and as a creator of nutraceutical health and wellness products, which include dietary supplements. It delivers phytochemicals such as age-defying antioxidants and polyphenols used for wellness. Its product pipeline is focused on polyphenols, which include grape cells, olive cells, and pomegranate cells. Its process involves selecting the specific plant cells that can create the targeted ingredients. It offers VINIA, which is a nutraceutical containing the entire matrix of polyphenols contained in red grapes, including Piceid resveratrol. It operates in the Healthcare sector.

Bioharvest Sciences Inc (BHST) is currently not a strong buy due to its low RSI of 32.086, indicating oversold conditions, and a significant year-to-date change of -69.87%. However, the company has shown revenue growth of 8% year-over-year in Q1 2026, with a projected annual revenue guidance of $42 million to $48 million, suggesting potential for recovery. The main risk is the forward P/E of 153.846, indicating high valuation expectations despite ongoing losses.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める